Do analysts rate PTIX or XBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Xenetic Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer PTIX or XBIO?

In the previous week, Xenetic Biosciences had 1 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Xenetic Biosciences and 1 mentions for Atrinsic. Xenetic Biosciences' average media sentiment score of 1.79 beat Atrinsic's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atrinsic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenetic Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts recommend PTIX or SNGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, PTIX or SNGX?

Soligenix is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M $2.23 0.35 Soligenix N/A N/A -$11.08M -$0.98 N/A

Is PTIX or SNGX more profitable?

Atrinsic's return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% Soligenix N/A -180.25% -107.46%

Does the media refer more to PTIX or SNGX?

In the previous week, Soligenix had 1 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Soligenix and 1 mentions for Atrinsic. Soligenix's average media sentiment score of 0.91 beat Atrinsic's score of 0.00 indicating that Soligenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atrinsic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Soligenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PTIX or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to PTIX or CDIO?

In the previous week, Cardio Diagnostics had 2 more articles in the media than Atrinsic. MarketBeat recorded 3 mentions for Cardio Diagnostics and 1 mentions for Atrinsic. Cardio Diagnostics' average media sentiment score of 1.19 beat Atrinsic's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atrinsic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend XTLB or PTIX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, XTLB or PTIX?

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XTL Biopharmaceuticals N/A N/A -$6.97M -$0.64 N/A Atrinsic N/A N/A -$5.53M $2.23 0.35

Is XTLB or PTIX more profitable?

Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Atrinsic N/A N/A -379.72%

Does the media prefer XTLB or PTIX?

In the previous week, XTL Biopharmaceuticals had 2 more articles in the media than Atrinsic. MarketBeat recorded 3 mentions for XTL Biopharmaceuticals and 1 mentions for Atrinsic. XTL Biopharmaceuticals' average media sentiment score of 0.94 beat Atrinsic's score of 0.00 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XTL Biopharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atrinsic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PTIX or AQB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atrinsic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, PTIX or AQB?

AquaBounty Technologies is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atrinsic N/A N/A -$5.53M $2.23 0.35 AquaBounty Technologies N/A N/A -$18.49M -$0.82 N/A

Is PTIX or AQB more profitable?

Atrinsic's return on equity of 0.00% beat AquaBounty Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Atrinsic N/A N/A -379.72% AquaBounty Technologies N/A -147.07% -28.73%

Does the media refer more to PTIX or AQB?

In the previous week, AquaBounty Technologies had 1 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for AquaBounty Technologies and 1 mentions for Atrinsic. AquaBounty Technologies' average media sentiment score of 0.91 beat Atrinsic's score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atrinsic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AquaBounty Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Atrinsic (PTIX) Competitors

$0.77 -0.04 (-5.21%)

As of 09/25/2026 02:04 PM Eastern

Compare

PTIX vs. XBIO, SNGX, CDIO, XTLB, and AQB

Should you buy Atrinsic stock or one of its competitors? Atrinsic's main competitors and comparable companies include Xenetic Biosciences (XBIO), Soligenix (SNGX), Cardio Diagnostics (CDIO), XTL Biopharmaceuticals (XTLB), and AquaBounty Technologies (AQB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Atrinsic compare to Xenetic Biosciences?

Atrinsic (NASDAQ:PTIX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Xenetic Biosciences has higher revenue and earnings than Atrinsic. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.35
Xenetic Biosciences	$2.98M	1.84	-$2.68M	-$1.16	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Xenetic Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 8.0% of Atrinsic shares are held by insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Xenetic Biosciences had 1 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Xenetic Biosciences and 1 mentions for Atrinsic. Xenetic Biosciences' average media sentiment score of 1.79 beat Atrinsic's score of 0.00 indicating that Xenetic Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atrinsic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenetic Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Atrinsic has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, Xenetic Biosciences has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market.

Atrinsic has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -75.90%. Atrinsic's return on equity of 0.00% beat Xenetic Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Summary

Xenetic Biosciences beats Atrinsic on 7 of the 12 factors compared between the two stocks.

How does Atrinsic compare to Soligenix?

Atrinsic (NASDAQ:PTIX) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Atrinsic has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market. Comparatively, Soligenix has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Atrinsic's return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Soligenix	N/A	-180.25%	-107.46%

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by insiders. Comparatively, 1.9% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Soligenix had 1 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for Soligenix and 1 mentions for Atrinsic. Soligenix's average media sentiment score of 0.91 beat Atrinsic's score of 0.00 indicating that Soligenix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atrinsic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Soligenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Soligenix is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.35
Soligenix	N/A	N/A	-$11.08M	-$0.98	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Atrinsic beats Soligenix on 6 of the 10 factors compared between the two stocks.

How does Atrinsic compare to Cardio Diagnostics?

Atrinsic (NASDAQ:PTIX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

8.0% of Atrinsic shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 8.0% of Atrinsic shares are held by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Atrinsic has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Atrinsic's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Atrinsic has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.28, suggesting that its share price is 128% more volatile than the broader market.

In the previous week, Cardio Diagnostics had 2 more articles in the media than Atrinsic. MarketBeat recorded 3 mentions for Cardio Diagnostics and 1 mentions for Atrinsic. Cardio Diagnostics' average media sentiment score of 1.19 beat Atrinsic's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atrinsic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Atrinsic has higher earnings, but lower revenue than Cardio Diagnostics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.35
Cardio Diagnostics	$14.45K	399.45	-$6.50M	-$2.92	N/A

Summary

Cardio Diagnostics beats Atrinsic on 7 of the 12 factors compared between the two stocks.

How does Atrinsic compare to XTL Biopharmaceuticals?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Atrinsic (NASDAQ:PTIX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, XTL Biopharmaceuticals had 2 more articles in the media than Atrinsic. MarketBeat recorded 3 mentions for XTL Biopharmaceuticals and 1 mentions for Atrinsic. XTL Biopharmaceuticals' average media sentiment score of 0.94 beat Atrinsic's score of 0.00 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XTL Biopharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atrinsic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Atrinsic	N/A	N/A	-379.72%

XTL Biopharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Atrinsic has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 8.0% of Atrinsic shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 8.0% of Atrinsic shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	N/A	N/A	-$6.97M	-$0.64	N/A
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.35

Summary

Atrinsic beats XTL Biopharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Atrinsic compare to AquaBounty Technologies?

Atrinsic (NASDAQ:PTIX) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

In the previous week, AquaBounty Technologies had 1 more articles in the media than Atrinsic. MarketBeat recorded 2 mentions for AquaBounty Technologies and 1 mentions for Atrinsic. AquaBounty Technologies' average media sentiment score of 0.91 beat Atrinsic's score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atrinsic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AquaBounty Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Atrinsic has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market.

Atrinsic's return on equity of 0.00% beat AquaBounty Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atrinsic	N/A	N/A	-379.72%
AquaBounty Technologies	N/A	-147.07%	-28.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atrinsic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AquaBounty Technologies is trading at a lower price-to-earnings ratio than Atrinsic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atrinsic	N/A	N/A	-$5.53M	$2.23	0.35
AquaBounty Technologies	N/A	N/A	-$18.49M	-$0.82	N/A

8.0% of Atrinsic shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 8.0% of Atrinsic shares are owned by company insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Atrinsic beats AquaBounty Technologies on 6 of the 10 factors compared between the two stocks.

Get Atrinsic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTIX vs. The Competition

Export

Metric	Atrinsic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.40M	$3.94B	$7.33B	$13.17B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-0.10	14.15	275.82	25.78
Price / Sales	N/A	1,438.70	649.60	92.85
Price / Cash	N/A	120.91	79.52	52.89
Price / Book	0.39	15.28	10.44	6.30
Net Income	-$5.53M	-$22.90M	$3.51B	$360.35M
7 Day Performance	-12.80%	-2.94%	-1.31%	-0.23%
1 Month Performance	-17.24%	-8.80%	-4.61%	-4.16%
1 Year Performance	-81.96%	28.99%	15.01%	4.58%

Atrinsic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTIX Atrinsic	0.0337 of 5 stars	$0.77 -5.2%	N/A	-82.0%	$1.40M	N/A	N/A	2	News Coverage
XBIO Xenetic Biosciences	0.9057 of 5 stars	$2.47 -2.0%	N/A	-22.7%	$5.89M	$2.98M	N/A	2	News Coverage
SNGX Soligenix	0.9303 of 5 stars	$0.39 +0.3%	N/A	-68.0%	$5.71M	$120K	N/A	14
CDIO Cardio Diagnostics	1.1198 of 5 stars	$1.93 +0.6%	N/A	-52.1%	$5.68M	$10K	N/A	1	News Coverage Positive News Short Interest Decrease
XTLB XTL Biopharmaceuticals	0.8856 of 5 stars	$2.41 +9.5%	N/A	N/A	$5.63M	$450K	N/A	10	News Coverage Positive News Short Interest Decrease High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTIX) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atrinsic (PTIX) Competitors

PTIX vs. XBIO, SNGX, CDIO, XTLB, and AQB

How does Atrinsic compare to Xenetic Biosciences?

Summary

How does Atrinsic compare to Soligenix?

Summary

How does Atrinsic compare to Cardio Diagnostics?

Summary

How does Atrinsic compare to XTL Biopharmaceuticals?

Summary

How does Atrinsic compare to AquaBounty Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atrinsic (PTIX) Competitors

PTIX vs. XBIO, SNGX, CDIO, XTLB, and AQB

How does Atrinsic compare to Xenetic Biosciences?

Which has preferable valuation & earnings, PTIX or XBIO?

Do analysts rate PTIX or XBIO?

Do insiders & institutionals hold more shares of PTIX or XBIO?

Does the media prefer PTIX or XBIO?

Which has more volatility & risk, PTIX or XBIO?

Is PTIX or XBIO more profitable?

Summary

How does Atrinsic compare to Soligenix?

Which has more risk & volatility, PTIX or SNGX?

Is PTIX or SNGX more profitable?

Do institutionals and insiders believe in PTIX or SNGX?

Does the media refer more to PTIX or SNGX?

Which has stronger earnings and valuation, PTIX or SNGX?

Do analysts recommend PTIX or SNGX?

Summary

How does Atrinsic compare to Cardio Diagnostics?

Do institutionals & insiders believe in PTIX or CDIO?

Is PTIX or CDIO more profitable?

Which has more risk and volatility, PTIX or CDIO?

Does the media refer more to PTIX or CDIO?

Do analysts recommend PTIX or CDIO?

Which has preferable valuation and earnings, PTIX or CDIO?

Summary

How does Atrinsic compare to XTL Biopharmaceuticals?

Does the media prefer XTLB or PTIX?

Is XTLB or PTIX more profitable?

Which has more risk & volatility, XTLB or PTIX?

Do analysts recommend XTLB or PTIX?

Do insiders & institutionals hold more shares of XTLB or PTIX?

Which has stronger earnings & valuation, XTLB or PTIX?

Summary

How does Atrinsic compare to AquaBounty Technologies?

Does the media refer more to PTIX or AQB?

Which has more risk & volatility, PTIX or AQB?

Is PTIX or AQB more profitable?

Do analysts recommend PTIX or AQB?

Which has better earnings & valuation, PTIX or AQB?

Do insiders & institutionals believe in PTIX or AQB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTIX vs. The Competition

Atrinsic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools